X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2021 16:05 ET
|
X4 Pharmaceuticals
BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
X4 Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4, 2021
October 25, 2021 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
X4 Pharmaceuticals Expands Commercial Leadership Expertise with Appointment of Françoise de Craecker to Board of Directors and Karolyn Park as Vice President, U.S. Commercial
October 19, 2021 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Oct. 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome
October 04, 2021 08:00 ET
|
X4 Pharmaceuticals
Final enrollment of 31 adult and pediatric patients exceeds initial target of 18-28 patients Top-line data expected in 4Q 2022; U.S. NDA filing anticipated in 1Q 2023 BOSTON, Oct. 04, 2021 (GLOBE...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 01, 2021 16:05 ET
|
X4 Pharmaceuticals
BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
X4 Pharmaceuticals to Participate in Upcoming Investor Conferences
September 15, 2021 16:05 ET
|
X4 Pharmaceuticals
BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting...
X4 Pharmaceuticals Promotes Mary DiBiase, Ph.D. to Chief Operating Officer
September 08, 2021 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2021 16:01 ET
|
X4 Pharmaceuticals
BOSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
X4 Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
September 01, 2021 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting...
X4 Pharmaceuticals to Participate at Canaccord Genuity’s Virtual 41st Annual Growth Conference
August 04, 2021 16:01 ET
|
X4 Pharmaceuticals
BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from...